Erin Burkhart insider trades: Biomarin Pharmaceutical (BMRN) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Erin reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | BMRN | ↓ Sell | 1,786 | $59.31 | $106K | Direct | May 20, 2025 (0d) |
| Mar 19, 2025 | BMRN | ↓ Sell | 1,295 | $71.52 | $93K | Direct | Mar 20, 2025 (1d) |
| Feb 24, 2025 | BMRN | ↓ Sell | 1,344 | $68.38 | $92K | Direct | Feb 25, 2025 (1d) |
| Aug 13, 2024 | BMRN | ↓ Sell | 714 | $90.00 | $64K | Direct | Aug 15, 2024 (2d) |
| Apr 10, 2024 | BMRN | ↓ Sell | 2,286 | $90.00 | $206K | Direct | Apr 12, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BMRN insiders
Open-market trades in the last 12 months
About Erin Burkhart's insider trades
Erin Burkhart is GVP, Chief Accounting Officer at Biomarin Pharmaceutical (BMRN). Since Apr 10, 2024, Erin has reported no open-market purchases and 5 sales worth $560K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include shares withheld for taxes (6 filings), grants and awards (6 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BMRN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.